OSE Immunotherapeutics : Public financing of € 8m to support the development of Tedopi
>A first step for the financing of phase III registration - Yesterday, OSE Immunotherapeutics announced that it was to receive public funds of up to € 8.4m to support the phase III clinical study for the registration of Tedopi in 2L for the treatment of non-small cell lung cancer (NSCLC), for HLA-A2 positive patients with secondary or acquired anti-PD(L)1 resistance. This non-dilutive financing come on foot of the call for “ i-Démo” projects as part of Bpifrance's Fra...Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.